CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions

Y Dauvilliers, CR Baumann, B Carlander, M Bischof, T Blatter, M Lecendreux, F Maly, A Besset, J Touchon, M Billiard, M Tafti, CL Bassetti

Objective: To determine the role of CSF hypocretin-1 in narcolepsy with and without cataplexy, Kleine-Levin syndrome (KLS), idiopathic and other hypersomnias, and several neurological conditions.

Patients: 26 narcoleptic patients with cataplexy, 9 narcoleptic patients without cataplexy, 2 patients with abnormal REM-sleep-associated hypersomnia, 7 patients with idiopathic hypersomnia, 2 patients with post-traumatic hypersomnia, 4 patients with KLS, and 88 patients with other neurological disorders.

Results: 23 patients with narcolepsy-cataplexy had low CSF hypocretin-1 levels, while one patient had a normal hypocretin level (HLA-DQB1*0602 negative) and the other two had intermediate levels (familial forms). One narcoleptic patient without cataplexy had a low hypocretin level. One patient affected with post-traumatic hypersomnia had intermediate hypocretin levels. The KLS patients had normal hypocretin levels while asymptomatic, but one KLS patient (also affected with Prader-Willi syndrome) showed a twofold decrease in hypocretin levels during a symptomatic episode. Among the patients without hypersomnia, two patients with normal pressure hydrocephalus and one with unclear central vertigo had intermediate levels.

Conclusion: Low CSF hypocretin-1 is highly specific (99.1%) and sensitive (88.5%) for narcolepsy with cataplexy. Hypocretin ligand deficiency appears not to be the major cause for other hypersomnias, with a possible continuum in the pathophysiology of narcolepsy without cataplexy and idiopathic hypersomnia. However, partial hypocretin lesions without low CSF hypocretin-1 consequences cannot be definitely excluded in those disorders. The existence of normal hypocretin levels in narcoleptic patients and intermediate levels in other rare aetiologies needs further investigation, especially for KLS, to establish the functional significance of hypocretin neurotransmission alterations.

Narcolepsy is characterised by two major symptoms, excessive daytime sleepiness (EDS) and cataplexy and other manifestations of abnormal rapid eye movement (REM) sleep. Although narcolepsy has been known as a distinct clinical entity for more than a century, it was only recently that a major discovery in its pathophysiology was made through the identification of orexin/hypocretin deficiency. While a single mutation in hypocretin genes has been found in one patient with atypical narcolepsy, undetectable levels of CSF hypocretin-1 were reported in most patients with sporadic narcolepsy and a dramatic decrease of hypocretin neurones in a few postmortem narcoleptic brains. Specificity and sensitivity of low CSF hypocretin-1 levels for human narcolepsy-cataplexy are very high.

Among the large narcoleptic populations reported, only a few patients had normal CSF hypocretin-1 levels and most were HLA DQB1*0602 negative, without cataplexy, or with a familial form of narcolepsy. The role of the hypocretin system in other hypersomnias is uncertain. Few studies reported normal CSF hypocretin-1 levels in most narcoleptic patients without cataplexy, in idiopathic hypersomnia, and in almost all other neurological disorders except for the Guillain-Barré syndrome and other rare conditions. Recently, a study reported CSF hypocretin deficiency in all patients affected with narcolepsy with or without cataplexy, and in idiopathic hypersomnia. The mechanism of differences between CSF hypocretin-1 levels and narcolepsy phenotype (with or without cataplexy, sporadic or familial, and whether HLA-associated or not) among studies remains controversial.

The hypocretin system might also be involved in other patients with hypersomnia. Among these, myotonic dystrophy and Prader-Willi syndrome share the presence of sleep onset REM periods (SOREMPs) with narcolepsy. The mechanism of hypersomnia with SOREMPs first suggested a central nervous system dysfunction; however the excessive daytime sleepiness may be in relation to sleep fragmentation that is secondary to frequent sleep-disordered breathing in those pathologies. Sleep apnoea syndrome could also share the presence of sleep onset REM periods with narcolepsy; however the mechanisms involved may be in relation to sleep deprivation only. Also, because the hypocretinergic neurotransmission plays a significant role in the regulation of both feeding and sleep-wake cycles, Kleine-Levin syndrome (KLS), which is characterised by recurrent hypersomnia and abnormal feeding behaviour, might represent a model disorder for hypocretin system malfunction. In this study, we investigated the CSF hypocretin-1 levels in different disorders with and without hypersomnia or feeding behaviour abnormalities and looked for phenotypic correlations with low hypocretin-1 levels.

Abbreviations: EDS, excessive daytime sleepiness; ICSD, international classification of sleep disorders; KLS, Kleine-Levin syndrome; MSLT, multiple sleep latency test; PLM, periodic leg movements; RDI, respiratory disturbances index; SOREMP, sleep onset REM period
PATIENTS AND METHODS

One hundred and thirty-eight unrelated patients were included. Three European collaborating centres contributed with 67 (YD, BC, JT, MBil, Montpellier, France, Centre 1), 69 (CRB, MBis, TB, FM, CLB, Zurich, Switzerland, Centre 2), and 2 patients (ML, Paris, France, Centre 3). Informed consent of all patients was obtained before lumbar puncture.

Sleep disorders were diagnosed clinically and using sleep studies. Patients were classified based on their primary ICSD (international classification of sleep disorders) diagnosis,21 blinded of CSF hypocretin-1 results. Demographic, clinical, polygraphic and HLA typing data are described in tables 1–4.

Sleep disorders were diagnosed clinically and using sleep studies. Patients were classified based on their primary ICSD (international classification of sleep disorders) diagnosis,21 blinded of CSF hypocretin-1 results. Demographic, clinical, polygraphic and HLA typing data are described in tables 1–4.

The cataplexy severity was assessed on a scale from 1 to 5, where: 1 = one cataplectic attack per year or fewer; 2 = more than one attack per year but less than one per month; 3 = more than one attack per month but less than one per week; 4 = more than one per week but less than one per day; and 5 = severe cases with at least one cataplectic attack per day. A mean respiratory disturbances index (RDI) including oesophageal pressure monitoring of less than 5 per hour and a periodic leg movements (PLM) index during sleep of less than 5 per hour were necessary to assess the primary sleep disorders diagnosis (—that is, narcolepsy without cataplexy, idiopathic hypersomnia, post-traumatic hypersomnia) except for narcolepsy with cataplexy.

Twenty-six (15 males and 11 females) narcoleptic patients with clear-cut cataplexy were included: three reported a positive family history of narcolepsy-cataplexy (major form) and three others a positive family history of isolated recurrent daytime naps or lapses into sleep (minor form)24 25 and all except one were HLA DQB1*0602 positive (table 1).

Nine (five males and four females) narcoleptic patients without cataplexy were included: two reported a positive family history of narcolepsy without cataplexy and all except one were HLA DQB1*0602 positive (table 2). Two other patients with SOREMP-associated hypersomnia were included: one with sleep apnoea syndrome and one with genetically confirmed myotonic dystrophy (expansion of 133 CTG repeat)26 and HLA DRB1*11/13 and DQB1*0301/0603 alleles (table 2). His sister was also affected with myotonic dystrophy and SOREMP-associated hypersomnia. Seven patients (five males and two females) with polysymptomatic idiopathic hypersomnia27 28 were included: one reported a positive family history of hypersomnia and three were HLA DQB1*0602 positive (table 2). Two more patients were affected with post-traumatic hypersomnia29 30 (table 2). The clinical history of case 1 revealed a severe traumatic brain injury with coma lasting for several days and the occurrence of excessive daytime sleepiness three months after. Brain MRI showed several small bilateral frontal and bilateral post-traumatic lesions without hypothalamic lesions. The second patient (case 2) had a less severe traumatic brain injury without coma or lesions, as revealed by MRI, with the occurrence of excessive daytime sleepiness two months after the trauma.

Four patients affected with Kleine-Levin syndrome were included (table 3). The diagnostic criteria were clinical and required at least (u) recurrent episodes of hypersomnia and (b) cognitive and mood disturbances present only during symptomatic episodes.21–23 The presence of the two other symptoms, hyperphagia and hypersexuality (in at least one symptomatic episode) was not necessary and was observed in

<table>
<thead>
<tr>
<th>Table 1</th>
<th>CSF hypocretin-1 in narcoleptic patients with cataplexy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects</td>
<td>Centre</td>
</tr>
<tr>
<td>1</td>
<td>36 F</td>
</tr>
<tr>
<td>2</td>
<td>53 F</td>
</tr>
<tr>
<td>3</td>
<td>57 M</td>
</tr>
<tr>
<td>4</td>
<td>52 M</td>
</tr>
<tr>
<td>5</td>
<td>33 M</td>
</tr>
<tr>
<td>6</td>
<td>39 M</td>
</tr>
<tr>
<td>7</td>
<td>19 F</td>
</tr>
<tr>
<td>8</td>
<td>20 F</td>
</tr>
<tr>
<td>9</td>
<td>22 M</td>
</tr>
<tr>
<td>10</td>
<td>17 M</td>
</tr>
<tr>
<td>11</td>
<td>55 M</td>
</tr>
<tr>
<td>12</td>
<td>35 M</td>
</tr>
<tr>
<td>13</td>
<td>55 M</td>
</tr>
<tr>
<td>14</td>
<td>13 F</td>
</tr>
<tr>
<td>15</td>
<td>29 M</td>
</tr>
<tr>
<td>16</td>
<td>23 F</td>
</tr>
<tr>
<td>17</td>
<td>26 F</td>
</tr>
<tr>
<td>18</td>
<td>51 F</td>
</tr>
<tr>
<td>19</td>
<td>26 F</td>
</tr>
<tr>
<td>20</td>
<td>64 M</td>
</tr>
<tr>
<td>21</td>
<td>34 M</td>
</tr>
<tr>
<td>22</td>
<td>22 M</td>
</tr>
<tr>
<td>23</td>
<td>52 M</td>
</tr>
<tr>
<td>24</td>
<td>29 M</td>
</tr>
<tr>
<td>25</td>
<td>18 F</td>
</tr>
<tr>
<td>26</td>
<td>37 F</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>35.3</td>
</tr>
<tr>
<td>(15)</td>
<td>(4.4)</td>
</tr>
</tbody>
</table>

Centre 1: Montpellier, France; Centre 2: Zurich, Switzerland
F, female; M, male; BMI, body mass index; EDS, excessive daytime sleepiness; E, Epworth sleepiness scale; C, cataplexy severity scale; HH, hypocretin-1 level in CSF (pg/ml); na, not available (adoptive child); Family history: 0, none; 1 = family history of narcolepsy; 2 = family history of hypersomnia
T, treatment: Psychostimulant or antidepressant treatment at time of CSF lumbar puncture
+Hypocretin-1 family history of narcolepsy without cataplexy
*Hypo-1 status cataplexic for several days when lumbar puncture was made
CSF hypocretin-1 levels in hypersomnias and neurological conditions

Hypocretin radioimmunoassay
Hypocretin-1 (orexin-A) was determined at least in duplicate from CSF samples without prior extraction using Hypocretin radioimmunoassay kits from Phoenix Peptide, Inc. according to the manufacturer’s prescriptions. The detection limit was 10 pg/ml and intra-assay variability was less than 10%. The mean daytime hypocretin-1 levels in the CSF of 47 published healthy controls is 363.2 (16.3) pg/ml (range 224–653) for the direct assay. Hypocretin-1 CSF levels less than 110 pg/ml were classified as low, between 110 and 200 pg/ml as intermediate and above 200 pg/ml as normal, as in Mignot et al.6

Statistical analysis
All results are reported as mean (standard deviation (SD)). For statistical analysis, the undetectable hypocretin level was arbitrarily set at 10 pg/ml (—that is, our detection limit). Between group comparisons were performed by analysis of variance. Tukey’s test was used after a significant result. Correlation coefficients were calculated according to Pearson’s method. Statistical significance was set at p<0.05.

### Table 2 CSF hypocretin-1 in patients with narcolepsy without cataplexy, idiopathic and other hypersomnias

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Centre</th>
<th>Age</th>
<th>Sex</th>
<th>Family history</th>
<th>E</th>
<th>C</th>
<th>HH</th>
<th>SP</th>
<th>MSLT</th>
<th>SOREMPs</th>
<th>RDI</th>
<th>Hypo-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Narcolepsy without cataplexy</td>
<td>1*</td>
<td>1</td>
<td>M</td>
<td>14</td>
<td>17</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>7</td>
<td>2</td>
<td>3.4</td>
<td>465</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>34</td>
<td>F</td>
<td>8</td>
<td>16</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>3.3</td>
<td>2</td>
<td>0.7</td>
<td>957</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>26</td>
<td>F</td>
<td>16</td>
<td>19</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>13.8</td>
<td>1</td>
<td>5</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>22</td>
<td>M</td>
<td>20</td>
<td>15</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>6.5</td>
<td>5</td>
<td>0.8</td>
<td>236</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>31</td>
<td>M</td>
<td>25</td>
<td>18</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>3</td>
<td>4</td>
<td>3.9</td>
<td>393</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>50</td>
<td>M</td>
<td>30</td>
<td>na</td>
<td>16</td>
<td>–</td>
<td>+</td>
<td>7</td>
<td>3</td>
<td>3.1</td>
<td>419</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>37</td>
<td>F</td>
<td>21</td>
<td>H</td>
<td>21</td>
<td>–</td>
<td>+</td>
<td>5.4</td>
<td>5</td>
<td>0.9</td>
<td>490</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>39</td>
<td>F</td>
<td>30</td>
<td>H</td>
<td>17</td>
<td>–</td>
<td>+</td>
<td>4</td>
<td>4</td>
<td>1.2</td>
<td>537</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>37</td>
<td>M</td>
<td>19</td>
<td>16</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>5.5</td>
<td>5</td>
<td>1.6</td>
<td>591</td>
</tr>
<tr>
<td>Idiopathic hypersomnia</td>
<td>1</td>
<td>31</td>
<td>M</td>
<td>31</td>
<td>19</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>4.4</td>
<td>1</td>
<td>1.1</td>
<td>609</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>36</td>
<td>M</td>
<td>26</td>
<td>14</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>5</td>
<td>0</td>
<td>1.4</td>
<td>204</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>61</td>
<td>M</td>
<td>21</td>
<td>17</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>5.2</td>
<td>0</td>
<td>2</td>
<td>327</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>28</td>
<td>F</td>
<td>22</td>
<td>H</td>
<td>16</td>
<td>–</td>
<td>+</td>
<td>4</td>
<td>0</td>
<td>1.1</td>
<td>342</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>49</td>
<td>F</td>
<td>37</td>
<td>15</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>6.4</td>
<td>0</td>
<td>1.8</td>
<td>400</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>36</td>
<td>M</td>
<td>30</td>
<td>17</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>7.1</td>
<td>0</td>
<td>3.5</td>
<td>421</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>41</td>
<td>M</td>
<td>35</td>
<td>14</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>4.2</td>
<td>0</td>
<td>0.9</td>
<td>1130</td>
</tr>
<tr>
<td>Post-traumatic hypersomnia</td>
<td>1</td>
<td>29</td>
<td>M</td>
<td>23</td>
<td>17</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>4.5</td>
<td>0</td>
<td>2</td>
<td>176</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>40</td>
<td>M</td>
<td>21</td>
<td>19</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>3</td>
<td>0</td>
<td>3.1</td>
<td>503</td>
</tr>
<tr>
<td>Sleep apnoea syndrome</td>
<td>1</td>
<td>49</td>
<td>M</td>
<td>14</td>
<td>22</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>2.1</td>
<td>4</td>
<td>27.8</td>
<td>476</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>23</td>
<td>M</td>
<td>19</td>
<td>18</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>6.4</td>
<td>3</td>
<td>5</td>
<td>401</td>
</tr>
</tbody>
</table>
| Centre 1: Montpellier, France; Centre 2: Zurich, Switzerland  
F, female; M, male; E, Epworth sleepiness scale; HH, hypnagogic hallucination; SP, sleep paralysis; RDI, respiratory disturbances index including oesophageal pressure monitoring; Hypo-1, level of hypocretin-1 in the CSF (pg/ml); na, not available  
* HLA DRB1*07/08-DQB1*02/04

### Table 3 CSF Hypocretin-1 in patients with Kleine-Levin syndrome

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Centre</th>
<th>Age</th>
<th>Sex</th>
<th>Family history</th>
<th>Cognitive alteration</th>
<th>Hyper-phagia</th>
<th>Hyper-sexuality</th>
<th>Triggering factor</th>
<th>Duration of episode</th>
<th>Number of episodes</th>
<th>HLA DQB1*</th>
<th>Hypo-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>15</td>
<td>M</td>
<td>13</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>10–20</td>
<td>5</td>
<td>0301/0301</td>
<td>897</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>16</td>
<td>F</td>
<td>15</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>1–10</td>
<td>5</td>
<td>0301/0302</td>
<td>453</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>24</td>
<td>F</td>
<td>16</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>4–12</td>
<td>8</td>
<td>na</td>
<td>268</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>21</td>
<td>M</td>
<td>20</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>14–16</td>
<td>2</td>
<td>0201/05</td>
<td>221/111</td>
<td></td>
</tr>
</tbody>
</table>

Centre 1: Montpellier, France; Centre 3: Paris, France  
Duration of episode = extreme values, in days  
na, not available  
Hypo-1, level of hypocretin-1 in the CSF (pg/ml) during asymptomatic periods except for patient 4, who had 221 pg/ml during asymptomatic periods and 111 pg/ml during symptomatic episodes
RESULTS

Narcolepsy with cataplexy

Between group comparisons of CSF hypocretin-1 levels indicated a highly significant difference ($F_{6,131} = 16.71$, $p < 0.0001$). Reanalysis showed that narcoleptic patients with cataplexy had lower hypocretin-1 levels than any other group ($p < 0.02$ to $p < 0.0002$). The overall 85th percentile of CSF hypocretin-1 levels was at 623 pg/ml for the whole population studied, with a high level arbitrarily set at 650 pg/ml.

The mean (SD) CSF hypocretin-1 level in narcoleptic patients with cataplexy was very low, 40.2 (60.2 pg/ml). Twenty-three narcoleptic patients with cataplexy had hypocretin-1 levels < 110 pg/ml, with 15 under the limit of detection, regardless of their current treatments (table 1). None had a high level (> 650 pg/ml). The hypocretin-1 level within the normal range (271 pg/ml) was found in only one patient (case 18), who had an unusual form of narcolepsy (long mean sleep latency on MSLT and negative HLA-DQB1*0602 typing) (table 1). This patient was our unique non-DQB1*0602 narcolepsy case. One narcoleptic patient with clear-cut cataplexy and positive HLA-DQB1*0602 typing had an intermediate CSF hypocretin-1 level (case 9, 126 pg/ml); however sleep inertia either after the night-time or daytime sleep was noted and several relatives with isolated recurrent daytime naps or lapses into sleep were identified in his family (table 1). The other narcoleptic patient with cataplexy and intermediate hypocretin-1 level (case 26, 145 pg/ml) was also a familial case with the mother affected with narcolepsy-cataplexy. Among the 26 narcoleptic probands, three reported a positive familial history of narcolepsy-cataplexy (cases 4, 17 and 26), three reported that relatives had isolated recurrent daytime naps or lapses into sleep (cases 9, 13 and 16) and all except two (case 9 and 26) had low CSF hypocretin-1 levels (table 1).

No association was found between CSF hypocretin-1 levels and sex, body mass index, age at onset of excessive daytime sleepiness or cataplexy, age and presence of treatment at the time of lumbar puncture, Epworth sleepiness scale, severity of cataplexy, mean sleep latencies on MSLT and the number of sleep onset REM periods. The CSF hypocretin-1 level in a patient with status cataplecticus was under the limit of detection (case 2, table 1). The sensitivity of low CSF hypocretin-1 levels (< 110 pg/ml) was 88.5% for narcoleptic patients with cataplexy, 92% for HLA-DQB1*0602 positive narcoleptic patients, and 95% for sporadic narcoleptic patients.

Narcolepsy without cataplexy, other SOREMP-associated hypersomnia, idiopathic and post-traumatic hypersomnia

The mean (SD) CSF hypocretin-1 level in narcoleptic patients without cataplexy was within the normal control range, 412.1

Table 4  CSF Hypocretin-1 in various neurological conditions

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>No</th>
<th>Centre</th>
<th>Sex</th>
<th>Age</th>
<th>Protein</th>
<th>Hypo-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s disease</td>
<td>8</td>
<td>1, 2</td>
<td>2M, 6F</td>
<td>70 (9.04)</td>
<td>0.50 (0.16)</td>
<td>483.87 (85.68)</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>3</td>
<td>2</td>
<td>1M, 2F</td>
<td>71 (13)</td>
<td>0.38 (0.11)</td>
<td>279.67 (58.01)</td>
</tr>
<tr>
<td>Motor neurone disease</td>
<td>4</td>
<td>1, 2</td>
<td>2M, 2F</td>
<td>67 (12.06)</td>
<td>0.31 (0.08)</td>
<td>462.75 (58.53)</td>
</tr>
<tr>
<td>Spasitic paraplegia</td>
<td>3</td>
<td>1, 2</td>
<td>1M, 2F</td>
<td>46.67 (20.13)</td>
<td>0.39 (0.04)</td>
<td>480.67 (74.78)</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>14</td>
<td>1, 2</td>
<td>6M, 8F</td>
<td>30.21 (10.21)</td>
<td>0.43 (0.10)</td>
<td>489.93 (244.56)</td>
</tr>
<tr>
<td>Devic disease</td>
<td>1</td>
<td>1</td>
<td>F</td>
<td>49</td>
<td>0.41</td>
<td>874</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>1</td>
<td>1</td>
<td>F</td>
<td>45</td>
<td>0.27</td>
<td>310</td>
</tr>
<tr>
<td>Peripheral neuropathies</td>
<td>1</td>
<td>1</td>
<td>F</td>
<td>45</td>
<td>0.27</td>
<td>310</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
<td>2</td>
<td>1, 2</td>
<td>2F</td>
<td>21.5 (6.36)</td>
<td>1.45 (1.2)</td>
<td>980.5 (193.04)</td>
</tr>
<tr>
<td>CIDP</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>60</td>
<td>1.77</td>
<td>1333</td>
</tr>
<tr>
<td>Diabetic neuropathy</td>
<td>2</td>
<td>1, M, F</td>
<td>54.5 (4.95)</td>
<td>0.79 (0.51)</td>
<td>493.5 (4.95)</td>
<td></td>
</tr>
<tr>
<td>Toxic polyneuropathy</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>57</td>
<td>0.48</td>
<td>427</td>
</tr>
<tr>
<td>Idiopathic polyneuropathy</td>
<td>3</td>
<td>1, 2</td>
<td>3F</td>
<td>55 (5.57)</td>
<td>0.5 (0.21)</td>
<td>850.33 (285.67)</td>
</tr>
<tr>
<td>Stroke</td>
<td>6</td>
<td>1</td>
<td>3M, 3F</td>
<td>65.67 (7.99)</td>
<td>0.33 (0.08)</td>
<td>617.00 (304.71)</td>
</tr>
<tr>
<td>Vascular dementia</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>70</td>
<td>0.65</td>
<td>391</td>
</tr>
<tr>
<td>Isolated CNS angiitis</td>
<td>1</td>
<td>2</td>
<td>2F</td>
<td>48</td>
<td>0.21</td>
<td>437</td>
</tr>
<tr>
<td>Paraneoplastic disorders</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>63</td>
<td>0.51</td>
<td>260</td>
</tr>
<tr>
<td>Lambert-Eaton syndrome</td>
<td>3</td>
<td>2</td>
<td>M</td>
<td>63.3 (14.64)</td>
<td>0.55 (0.32)</td>
<td>448 (122.87)</td>
</tr>
<tr>
<td>Limbic encephalitis</td>
<td>3</td>
<td>2</td>
<td>3F</td>
<td>63.3 (14.64)</td>
<td>0.55 (0.32)</td>
<td>448 (122.87)</td>
</tr>
<tr>
<td>Prion diseases</td>
<td>5</td>
<td>2</td>
<td>5M</td>
<td>65.2 (10.69)</td>
<td>0.49 (0.12)</td>
<td>536.56 (55.28)</td>
</tr>
<tr>
<td>Creutzfeldt-Jacob disease</td>
<td>3</td>
<td>1</td>
<td>2M, 1F</td>
<td>70.67 (2.88)</td>
<td>0.43 (0.08)</td>
<td>477.67 (575.77)</td>
</tr>
<tr>
<td>Normal pressure hydrocephalus</td>
<td>1</td>
<td>2</td>
<td>M</td>
<td>40</td>
<td>0.45</td>
<td>588</td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td>4</td>
<td>2</td>
<td>4F</td>
<td>36.25 (5.56)</td>
<td>0.30 (0.09)</td>
<td>533.83 (498-563)</td>
</tr>
<tr>
<td>Pseudotumour cerebri</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>72</td>
<td>0.51</td>
<td>382</td>
</tr>
<tr>
<td>CNS neoplasm</td>
<td>2</td>
<td>1</td>
<td>F</td>
<td>50</td>
<td>0.23</td>
<td>531</td>
</tr>
<tr>
<td>Myoclonus-hyperslexia</td>
<td>1</td>
<td>2</td>
<td>F</td>
<td>32</td>
<td>0.22</td>
<td>501</td>
</tr>
<tr>
<td>Lues</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>49</td>
<td>0.5</td>
<td>821</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>1</td>
<td>1</td>
<td>M</td>
<td>49</td>
<td>0.5</td>
<td>821</td>
</tr>
<tr>
<td>Central vertigo</td>
<td>3</td>
<td>1</td>
<td>2M, 1F</td>
<td>39 (20.24)</td>
<td>0.43 (0.13)</td>
<td>695.33 (457.07)</td>
</tr>
<tr>
<td>Acute headache</td>
<td>1</td>
<td>2</td>
<td>2M, 1F</td>
<td>39.33 (5.56)</td>
<td>0.47 (0.04)</td>
<td>993.33 (35.51)</td>
</tr>
<tr>
<td>Epileptic seizures</td>
<td>4</td>
<td>1, 2</td>
<td>2M, 2F</td>
<td>57.5 (9.54)</td>
<td>0.39 (0.14)</td>
<td>677.75 (213.88)</td>
</tr>
<tr>
<td>Chronic sciatia</td>
<td>1</td>
<td>1</td>
<td>F</td>
<td>34</td>
<td>0.55</td>
<td>5983</td>
</tr>
<tr>
<td>Cranio-cerebral trauma</td>
<td>1</td>
<td>1</td>
<td>3F</td>
<td>63</td>
<td>1.59</td>
<td>5983</td>
</tr>
<tr>
<td>Depression</td>
<td>1</td>
<td>2</td>
<td>M</td>
<td>38</td>
<td>0.31</td>
<td>595</td>
</tr>
<tr>
<td>Encephalitis</td>
<td>1</td>
<td>2</td>
<td>F</td>
<td>23</td>
<td>0.21</td>
<td>589</td>
</tr>
<tr>
<td>Other dementia</td>
<td>2</td>
<td>1</td>
<td>M</td>
<td>71</td>
<td>0.42</td>
<td>456</td>
</tr>
<tr>
<td>Recurrent attacks of dizziness</td>
<td>1</td>
<td>2</td>
<td>M</td>
<td>62</td>
<td>0.40</td>
<td>1259</td>
</tr>
</tbody>
</table>

Centre 1: Montpellier, France; Centre 2: Zurich, Switzerland

Protein = CSF protein expressed in g/ml

Hypo-1 = mean (SD) range level of hypocretin-1 in the CSF (pg/ml)

*CIPD, Chronic inflammatory demyelinating polyneuropathy; CNS, central nervous system
levels in 23 out of 26 (88.5%) narcoleptic patients with hypersomnia and the first in patients with well-defined case series of CSF hypocretin-1 measurements in patients The population of this study constitutes the second largest cataplexy did not differ in terms of CSF hypocretin-1 level.

Two other SOREMP-associated hypersomnia patients affected with sleep apnoea syndrome and myotonic dystrophy had normal CSF hypocretin-1 levels (table 2).

All of the patients with polysymptomatic idiopathic hypersomnia had CSF hypocretin-1 levels above 200 pg/ml with a mean (SD) level at 490.4 (307.4) pg/ml (table 2). One patient had an atypically high CSF hypocretin-1 level (1130 pg/ml); the lumbar puncture was performed during a period of shift work accompanied by sleep deprivation.

The patient most severely affected with post-traumatic hypersomnia with brain lesions (as determined by MRI) had an intermediate CSF hypocretin-1 level (176 pg/ml), while the second most severely affected patient had a normal level (table 2).

Patients with Kleine-Levin syndrome

The mean (SD) CSF hypocretin-1 level in this group during the asymptomatic periods was within the normal control range, 459.8 (308.2) pg/ml (table 3). However, one patient (case 1) had a high CSF hypocretin-1 level (897 pg/ml). CSF samples were available during both asymptomatic and symptomatic periods in case 4. Results showed a twofold decrease in hypocretin-1 level during the hypersomnia (111 pg/ml) episode as compared to the asymptomatic period (221 pg/ml) (table 3). This patient was affected with both Kleine-Levin syndrome and Prader-Willi syndrome.

Other neurological conditions

The mean CSF hypocretin-1 level in this group was 572.4 (268.5) pg/ml. For the 88 patients investigated, CSF hypocretin-1 levels were intermediate in three cases, and no cases had low levels (table 4). In three patients affected with normal pressure hydrocephalus, two had intermediate CSF hypocretin-1 levels (123 and 168 pg/ml respectively) and one had a high CSF hypocretin-1 level (1142 pg/ml). The third patient with an intermediate CSF hypocretin-1 level (177 pg/ml) was affected with central vertigo without clear organic aetiology. One patient with Parkinson’s disease, one patient with Alzheimer’s disease, one patient with motor neurone disease, and one patient with an intermediate CSF hypocretin-1 level had high CSF hypocretin-1 levels in idiopathic hypersomnia. 19

In our neurological disorder population, CSF hypocretin-1 levels showed the largest variance (from 123 to 1333 pg/ml) (table 4). Seventeen patients with various neurological conditions had high CSF hypocretin-1 level (>650 pg/ml) and nine of those had levels above 1000 pg/ml (table 4). A weak correlation was found between CSF hypocretin-1 and CSF protein levels (r = 0.24, p < 0.028). No association was found between sex, body mass index, or age at time of lumbar puncture and CSF hypocretin-1 levels.

DISCUSSION

The population of this study constitutes the second largest case series of CSF hypocretin-1 measurements in patients with hypersomnia and the first in patients with well-defined Kleine-Levin syndrome. The presence of a low CSF hypocretin-1 level is highly specific (99.1%) and sensitive (88.5%) for narcolepsy with cataplexy. We found low CSF hypocretin-1 levels in 23 out of 26 (88.5%) narcoleptic patients with cataplexy. One HLA DQB1*0602 negative patient had a normal hypocretin-1 level and two patients with intermediate levels were from familial cases (major and minor phenotype), findings confirming earlier reports. 7–11 13 14 We found normal CSF hypocretin-1 levels in eight out of nine (88.9%) narcoleptic patients without cataplexy, a finding also reported in most previous studies. 9 11 14 15 These findings strengthen the role of cataplexy (but not its severity) in the positive diagnosis of full-blown narcolepsy and suggest a different aetiology for narcolepsy without cataplexy. However, several narcoleptic patients with clear-cut cataplexy and normal or high CSF hypocretin-1 levels have been reported as well as narcoleptic patients without cataplexy but with low CSF hypocretin-1 levels 9 11 15 34 39 (also observed in our population). Moreover, a dramatic decrease in the number of hypocretin-containing neurones of the hypothalamus has been reported in postmortem brains of both narcoleptic patients with and without cataplexy. 4 We hypothesise a continuum of severity progressing from narcolepsy without cataplexy to narcolepsy with cataplexy with a defective hypocretin neurotransmission in rare cases. CSF hypocretin-1 level is also closely associated with the presence of HLA DQB1*0602 allele since the only DQB1*0602 negative narcoleptic-cataplectic patient in our population had normal hypocretin levels, a finding in agreement with the literature. 8 9 11 14 31 In addition, among the six narcoleptic patients with relatives affected either with narcolepsy-cataplexy or isolated daytime naps or lapses into sleep, two had intermediate hypocretin levels, suggesting a weaker association between low hypocretin levels and familial narcolepsy. These findings confirm the earliest reports 4 14 33 and suggest that the DQB1*0602 allele may have a major role in conferring low or absent hypocretin neurotransmission. Other SOREMP-associated hypersomnias included in this study (sleep apnoea syndrome and myotonic dystrophy) were associated with normal CSF hypocretin-1 levels. These results do not support the involvement of hypocretin transmission in abnormal regulation of REM sleep in these conditions, although only a few non-narcoleptic patients with SOREMPs associated hypersomnia were investigated.

Polysymptomatic idiopathic hypersomnias were associated with normal CSF hypocretin levels as also recently reported by others. 9 11 14 Only one study reported a hypocretin deficiency (<100 pg/ml) in idiopathic hypersomnia. 19 In our population, one patient with sleep debt associated with shift work and idiopathic hypersomnia had a high CSF hypocretin level. Head trauma is another rare cause of hypersomnia in which CSF hypocretin levels were rarely investigated. 7 Two head trauma patients with objective hypersomnia were included, one with an intermediate and one (less severe condition) with a normal CSF hypocretin-1 level. Although the involvement of hypocretin transmission abnormality remains uncertain in this condition, the long delay between brain injury, the occurrence of excessive daytime sleepiness, and the time of lumbar puncture may have confounded the results.

In addition to previous data, 9 11 14 15 33 our results in several hypersomnia conditions strengthen the absence of CSF hypocretin-1 deficiency in the pathophysiology of most of non narcolepsy-cataplexy disorders. A hypothesis may be drawn for continuum in the pathophysiology of narcolepsy without cataplexy and idiopathic hypersomnia. However, a dysfunction in hypocretin-1 or 2 receptor, an ineffective signal neurotransmission or only partial hypocretin lesions without low CSF hypocretin-1 consequences cannot be definitely excluded in those disorders.

Kleine-Levin syndrome is a rare cause of hypersomnia characterised by a recurrent alteration of sleep-wake regulation and frequent abnormal feeding and sexual behaviours. 21–23
Recent association reported with HLA DQB1*0201 together
with the young age of onset, the recurrence of symptoms, and
the frequent infectious precipitating factors suggest an
autoimmune aetiology for Kleine-Levin syndrome. Since
the role of hypocretin neuropeptides in both feeding
behaviour and sleep-wake regulation is now well estab-
lished,66 we have hypothesised a hypocretin neurotransmis-
sion abnormality in patients with Kleine-Levin syndrome.
The four cases investigated during an asymptomatic interval
had CSF hypocretin-1 levels in the normal range, but one
patient investigated both between and within symptomatic
periods had a twofold decrease in hypocretin-1 level during
the symptomatic episode (this patient was also affected
with Prader-Willi syndrome), suggesting a possible intermittent
alteration of the hypocretin system. This finding constitutes
the first report of a specific and transient decrease in CSF
hypocretin-1 level in association with recurrent clinical
symptoms. Recently two other patients with Kleine-Levin
syndrome have been investigated during symptomatic
episodes, one with intermediate7 and the other with normal10
CSF hypocretin-1 levels, but no data were available during
their normal interval period. Another patient affected with
Prader-Willi syndrome but without Kleine-Levin syndrome
has been reported in the literature with an intermediate
hypocretin level (111 pg/ml),3 confirming our hypothesis that
episodic and state-dependent variations in hypocretin levels
might occur in Kleine-Levin syndrome, either isolated or
associated with Prader-Willi syndrome, and might therefore
represent a biological marker of these disorders.

Finally, patients (3.4%) with other rare neurological
conditions had intermediate but never low normal CSF hypocretin-1
levels. Mignot et al12 reported recently that out of 194
neurological patients, 30 (15.5%) had intermediate levels and
three had low levels in various acute neuropathological
conditions. Another striking finding is the intermediate
hypocretin-1 level in normal pressure cerebral hydrocephalus (two
out of three patients), but not in Guillon-Barré syndrome,
cranioectodermal tumour (without hypersomnia), paraneoplastic
or encephalitis disorders as previously reported.12 13 14 15 16
In contrast, high CSF hypocretin-1 levels occurred in several
neurological conditions (including mild Guillian-Barré syn-
drome,34 35 36 and both idiopathic hypersomnia (one patient)
and Kleine-Levin syndrome (one patient). Similar results
were previously reported in early-onset restless legs syn-
drome.37 The high CSF hypocretin-1 level (>650 pg/ml) was
statistically calculated above the 85th percentile of our
overall population, but an upper limit of normal CSF is not yet
known. In contrast to most patients with hypersomnia, a
large variation in CSF hypocretin-1 levels was observed in the
heterogeneous neurological group although the importance of
these findings remain controversial.38 39 40 41 In spite of a
weak correlation found between CSF protein and hypocretin-1
levels in this group, the heterogeneity in CSF hypocretin-1
levels was not explained. However, the significance of intermediate
(110–200 pg/ml) and high hypocretin
(>650 pg/ml) levels is still unclear and needs further investigation.

Summary
Deficient hypocretin-1 transmission is highly specific and
sensitive for narcolepsy, associated with Prader-Willi syndrome, and might therefore
occur in Kleine-Levin syndrome, either isolated or
associated with Prader-Willi syndrome. The involvement of intermediate level of CSF hypocretin-1 in
non-narcoleptic conditions therefore remains unclear. We may suggest a focal, transient, and immune-modulated
process in the hypothalamic hypocretin system in Kleine-Levin syndrome, resulting in altered hypocretin neurotrans-
mition only during symptomatic episodes.

Authors’ affiliations
Y Davuilliers, B Carlander, J Touchon, M Billiard, Service de Neurologie
B, Hôpital Gui-de-Chauliac, Montpellier, France
Y Davuilliers, M Tafti, Biochemistry and Genetics, Department of
Psychiatry, Geneva, Switzerland
Y Davuilliers, A Besset, J Touchon, INSERM E0361, Hôpital la
Colombière, Montpellier, France
C R Baumann, M Bischof, T Blatter, C L Bassetti, Neurology Clinic,
University Hospital Zurich, Switzerland
M Lecendreux, Service de Psychopathologie de l’Enfant et de
l’Adolescent, Hôpital Robert Debré, Paris, France
F Maly, Institute of Clinical Chemistry, University Hospital Zurich,
Switzerland
YD and MT were supported by the Geneva University Hospitals.

REFERENCES
2 Gelineau JBE. De la narcolepsie. Gazette des Hôpitaux (Paris)
3 Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a
4 Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in knockout mice:
narcolepsy and a generalized absence of hypocretin peptides in human
6 Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin
8 Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orxin levels in
9 Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid
hypocretin measurement in the diagnosis of narcolepsy and other
10 Dalal MA, Schuld A, Haack M, et al. Normal plasma levels of orexin A
11 Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A)
concentrations in narcolepsy with and without cataplexy and idiopathic
concentrations in cerebrospinal fluid are low in patients with Guillon-Barré
multimodal diagnostic approach including cerebrospinal fluid levels of
14 Kahan LE, Pankratz VS, Oliver L, et al. Hypocretin (orexin) levels in
cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and
15 EBrahim IQ, Shareif MK, Deluca S, et al. Hypocretin (orexin) deficiency in
narcolepsy and primary hypersomnia. J Neurol Neurosurg Psychiatry
16 Gibbs JW 3rd, Castiglioni E, Radhke RA. Excessive daytime somnolence and
increased rapid eye movement pressures in myasthenic dystrophy. Sleep
2002;25:672–5.
17 Guilleminault C, Strohs R, Quero-Salva MA. Sleep-related obstructive and
clinical-electrophysiological features and underlying factors. Clin
Neurophysiology 2001;112:800–5.
19 Chervin RD, Aldrich MS. Sleep onset REM periods during multiple sleep
latency tests in patients evaluated for sleep apnea. Am J Respir Crit Care Med
20 Willie JT, Chemelli RM, Sinton CM, et al. To eat or to sleep? Orexin in the
21 American Sleep Disorders Association. International classification of sleep
disorders, revised: Diagnostic and coding manual. Rochester, MN: American
22 Davuilliers Y, Mayer G, Lecendreux M. Kleine-Levin syndrome: an
autoimmune hypothesis based on clinical and genetic analyses. Neurology
23 Billiard M. The Kleine Levin syndrome. In: Kryger MH, Roth T, Dement WC,
ed. Principles and Practice of Sleep Medicine. Philadelphia: WB Saunders,
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions

Y Dauvilliers, CR Baumann, B Carlander, M Bischof, T Blatter, M Lecendreux, F Maly, A Besset, J Touchon, M Billiard, M Tafti and C L Bassetti

*J Neurol Neurosurg Psychiatry* 2003 74: 1667-1673
doi: 10.1136/jnnp.74.12.1667

Updated information and services can be found at: http://jnnp.bmj.com/content/74/12/1667

These include:

**References**

This article cites 32 articles, 7 of which you can access for free at: http://jnnp.bmj.com/content/74/12/1667#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Sleep disorders (neurology) (151)
- Drugs: CNS (not psychiatric) (1945)
- Sleep disorders (143)
- Ear, nose and throat/otolaryngology (208)
- Hydrocephalus (134)

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/